Esperion Therapeutics Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 11 of 11 Posts
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich Friday, January 26, 2018 6:44 PM EDT
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
3 Of The Best & Worst Performing Drug Stocks Of Q1
Article By: Arpita Dutt Thursday, April 6, 2017 11:37 AM EDT
Pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, in the first quarter of 2017.
In this article: ESPR, VRTX, NKTR, ARGS, CDTX, XENE
Read
Ruling By FDA Causes Shares Of Esperion Therapeutics, Inc. To Jump 50% Today
Article By: Lorimer Wilson Monday, March 20, 2017 3:23 PM EDT
Esperion announced this morning that the FDA is willing to sign off on an approval for its lead drug - provided it clears LDL lowering goals in a pivotal study - without a cardio study as a prerequisite. Its shares soared more than 50% on the news.
In this article: AMGN, ESPR
Read
Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations
Article By: Rod Raynovich Friday, March 17, 2017 10:17 AM EDT
Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered four stocks: AMGN, ESPR, MDCO and REGN.
In this article: AMGN, REGN, MDCO, ESPR Also: IBB, XBI, XLV
Read
Healthcare Stocks Lead On A Lackluster Day
Article By: Rod Raynovich Monday, April 4, 2016 8:30 PM EDT
Lagging healthcare and biotech stocks found buyers today. The healthcare SPDR ETF was up 1.05% to $69.38 as investors were probably seeking dividends and safety with fears about pricing tempered.
In this article: BMY, EW, RHHBY, ACAD, ALNY, ALXN, ANAC, IBB, GILD, NBIX, VRTX, ZIOP, XBI, XLV, ESPR, ABBV, KITE, BLUE, EDIT
Read
EC Five Pharma Picks For 2016: Credit Suisse
Article By: ValueWalk Wednesday, December 23, 2015 3:34 AM EDT
Analysts at Credit Suisse believe that 2016 is set to be yet another volatile year for the sector, especially small and mid-cap names. However, they believe that seven pharmaceutical names have what it takes to outperform.
In this article: ALKS, ESPR, PTLA, MYOK, ADMS
Read
E Shares Of Esperion Tumbled 48% After End-Of-Phase-2 Meeting With FDA
Article By: Terry Chrisomalis Tuesday, September 29, 2015 7:56 PM EDT
The release of the minutes of Esperion's meeting with the FDA showed that the company still has a long road before it can bring its cholesterol drug to market.
In this article: ESPR, REGN, SNY, AMGN
Read
Are You Ready For A Pullback?
Article By: Andy Wang Thursday, August 6, 2015 11:28 PM EDT
Stocks reversed the morning gains on Thursday and ended lower. The Dow was down 120.72 points (-0.69%); Nasdaq fell 83.5 points (-1.62%); SPX dropped 16.28 points (-0.78%).
In this article: , APA, APC, CRM, DO, EOG, RHT, RIG, SLB, JAZZ, ADBE, AMGN, AMZN, BIIB, CELG, CLVS, GILD, GOOG, MSFT, NFLX, PCLN, UTHR, IGV, ESPR, FB, PANW, SPX, GOOGL
Read
E Shares Of Regeneron And Esperion Are Down Today On Cholesterol Panel Vote
Article By: Terry Chrisomalis Wednesday, June 10, 2015 11:04 AM EDT
Shares of Regeneron and Esperion are down after panel recommends approval for new class of Cholesterol drugs but requires larger studies to approve for bigger patient population.
In this article: REGN, SNY, ESPR
Read
Esperion Therapeutics Announces Positive Phase 2b Results For Cholesterol-Lowering Drug
Article By: Terry Chrisomalis Tuesday, March 17, 2015 7:21 PM EDT
Shares of Esperion soar 29% after the company reported positive Phase 2b results in patients with hypercholesterolemia.
In this article: ESPR
Read
FDA Removes Partial Clinical Hold For Esperion's Drug For Bad Cholesterol
Article By: Terry Chrisomalis Tuesday, February 3, 2015 11:56 AM EDT
Shares of Esperion surged as much as 20% on the news that the FDA removed the partial clinical hold for ECT-1002.
In this article: ESPR
Read
1 to 11 of 11 Posts